Crinetics Pharmaceuticals CRNX Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's investment proceeds?
- Crinetics Pharmaceuticals (CRNX) reported investment proceeds of $302.89M in Q1 2026.
- How has Crinetics Pharmaceuticals's investment proceeds changed year-over-year?
- Crinetics Pharmaceuticals's investment proceeds decreased by 1.2% year-over-year, from $306.48M to $302.89M.
- What is the long-term trend for Crinetics Pharmaceuticals's investment proceeds?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's investment proceeds has grown at a 103.3% compound annual growth rate (CAGR), from $69.36M to $1.18B.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.